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ABSTRACT 
 
OBJECTIVE: The objective of this selective evidence based medicine review is to 
determine whether or not “herbal medicine has an effect on the cognitive function of 
patients with mild to moderate Alzheimer’s disease over the age of 50”. 
 
STUDY DESIGN: Review of three double-blind, randomized control trials published 
between 2003 and 2015. All studies were published in English language in peer reviewed 
journals. 
 
DATA SOURCES: Three randomized control trials were found via PubMed. 
 
OUTCOMES MEASURED: The outcomes measured include changes in Alzheimer’s 
symptoms based upon a neurologist, improvement of Alzheimer’s symptoms based on 
ADAS-cog and CDR-SOB clinical rating scale, and Alzheimer health related quality of 
life based on a 20-item questionnaire. 
 
RESULTS: Akhondzadeh et al (2003) demonstrated a significant reduction in 
Alzheimer’s symptom scores after treatment with herbal medicine, Salvia officinalis 
extract, with a p value of <0.0001. Tajadini et al (2005) demonstrated a significant 
reduction in Alzheimer’s symptom scores after treatment with herbal medicine, Davaie 
Loban, with a p value of <0.001.  Zhang et al (2015) demonstrated a significant reduction 
in Alzheimer’s symptom scores after treatment with herbal formula, Yishen Huazbuo 
decoction, with a p value of <0.05. 
 
CONCLUSIONS: Results of the three studies demonstrate that herbal medicine is an 
effective treatment in individuals over the age of 50 for the cognitive improvement of 
mild to moderate Alzheimer’s disease. Two studies recommend that further studies 
should be done with longer follow-ups and larger sample sizes to more confidently 
confirm the findings.  
 
KEY WORDS: Alzheimer’s disease, herbal medicine, cognitive function  
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INTRODUCTION 
 
Alzheimer’s Disease is an irreversible and chronic brain disorder that occurs when brain 
tissue is changed and destroys memory and thinking skills. As the population living of the United 
States is continuing to age, Alzheimer’s is becoming a more prevalent cause of death5. This 
decline happens because neurons that are involved in cognitive function slowly become damaged 
over time and do not function properly4. Alzheimer’s is a common disease. Experts suggest that 
5.5 million Americans have Alzheimer’s disease and one in nine people age 65 and older are 
affected. It is estimated that the total annual healthcare cost for Alzheimer’s disease is $259 
billion dollars5. They even state that there are 780 hospital stays per 1,000 Medicare beneficiaries 
age 65 and older with Alzheimer’s disease and other dementias4. 
The exact cause of Alzheimer’s is unknown; however, it has been found that the 
symptoms it causes seem to come from nerve damage. Nerve cells get tangles called 
neurofibrillary tangles and protein deposits called beta-amyloid plaques that build up in the 
brain. These brain changes are believed to contribute to the development of Alzheimer’s. 
Eventually, the number of synapses decrease, information transfer at synapses decline, and 
neurons begin to die6. The most common symptoms of Alzheimer’s disease include memory loss 
that disrupts daily life, challenges in solving problems, confusion with time and place, trouble 
understanding visual images and relationship, and problem with words in both speaking and 
writing. There are numerous complications of Alzheimer’s including immobility, swallowing 
disorders, malnutrition, and pneumonia4.  
 There is no cure for Alzheimer’s disease, but medications and sensory therapy can help 
its symptoms and slow the progression4. Non-pharmacologic therapies include music therapy and 
reminiscence therapy. Previous published research has shown that exercise, gardening, word 
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games, and listening to music can show assurance. Lifestyle modifications also include schedule 
toileting to reduce incontinence, daily routines, and encourage social interaction4. However, 
current pharmacologic therapies as well as non-pharmacologic therapies have not been shown to 
alter the viscous course of Alzheimer’s disease. There are different types of drugs that can target 
treatment of memory loss, sleep problems, behavior changes, and other symptoms associated 
with Alzheimer’s. It is recommended to treat depression and irritability with selective serotonin 
reuptake inhibitors (SSRI) such as citalopram (Celexa). For people experiencing anxiety, 
medicine such as alprazolam (Niravam, Xanax) may be beneficial. Cholinesterase inhibitors such 
as Donezepil (Aricept) are the treatment of choice for people experiencing mild to moderate 
symptoms of Alzheimer’s. N-methyl-D-aspartate receptor blocker such as Memantine 
(Namenda) is offered to people experiencing more severe symptoms6. 
 Though there is no cure for Alzheimer’s disease, effective control of the symptoms is an 
attainable goal. Despite the existence of effective treatments for sleep problems and behavior 
changes, there continues to be an effort to find an effective treatment to improve cognitive 
function. It is for this reason that several randomized control trials have been carried out in an 
attempt to scientifically show the effectiveness of improving cognitive function with herbal 
medicine.  
OBJECTIVE 
The objective of this selective evidence based medicine review is to determine whether or 
not “herbal medicine has an effect on the cognitive function of patients with mild to moderate 
Alzheimer’s disease over the age of 50?” 
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METHODS  
 Criteria: This selective evidence based medicine review evaluates three randomized 
control trials chosen based on population, intervention, comparison group, and outcomes 
measures. The selected population of interest was patients 50 years or older with a diagnosis of 
mild to moderate Alzheimer’s disease. The intervention in these three studies was the treatment 
of herbal medicines. The treatment group receiving Salvia Officinalis extract, Davaie Loban, or 
Chinese herbal formual Yishen Huazbuo decoction was compared to a group receiving a visually 
matched placebo or herbal formula donepezil hydrochloride. The outcomes measured in these 
studies included the effect on the patient’s cognitive function and activities of daily living.  
 Data Sources: The key words “Alzheimer’s disease”, “herbal medicine”, and “cognitive 
function” were searched on PubMed to find articles both relevant to the clinical question and 
ones that included patient oriented outcomes (POEMS: Patient Orientated Evidence that 
Matters). All articles were published in the English language between 2003 and 2015 in peer-
reviewed journals. The inclusion criteria included double-blind studies published after 2000 and 
exclusion criteria included patients under 50 years old. The statistics used and reported in the 
selective based medicine review include p-value and change in mean from baseline with a 
standard deviation.  
Table 1- Demographics & Characteristics of Included Studies  
Study Type # 
Pts 
Age 
(years) 
Inclusion criteria Exclusion criteria W/
D 
Interventions 
Akhond
zadeh, 
2003  
(1) 
Double-
blind, 
RCT 
39 Salvia 
extract: 
71.78 ± 
3.67 
 
Placebo
: 
72.75 ± 
3.43 
Patients between 65 and 80, 
patients with a history of 
cognitive decline for at 
least 6 months, diagnosed 
with ALZ according to the 
NINCDS/ADRDA, ADAS-
cog ≥12 and CDR-SOB ≤2, 
any other medication to 
treat dementia must be d/c, 
Evidence of other 
neurodegenerative 
disorders, any 
cardiovascular 
disease, active 
peptic ulcer, 
urinary outflow 
obstruction, 
history of 
9 Salvia 
officinalis 
extract 
delivered 60 
drops/day for 
4 months   
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HTN, HF, DM were 
included provided the 
disease was controlled 
epilepsy, drugs 
with 
anticholinergic 
effects Tajadini 
2015 
(2) 
 
Double-
blind, 
RCT 
50 Davaie 
Loban 
66.25  
± 6.25 
 
Placebo
: 
67.65 ± 
5.99 
Patients older than 50, 
diagnosed with mild to 
moderate ALZ, ADAS-
cog≥12 and CDR-SOB ≤2, 
brain CT or MRI were 
examined to rule out multi-
infarct dementia or 
cerebrovascular diseases 
Cardiovascular 
disease, illicit 
drug use, DM, 
epilepsy, 
cerebrovascular 
disease, 
neurodegenerative 
disorders, taking 
coagulants  
6 Davaie Loban 
capsules 
(500g, three 
times daily, 
every 8 hours) 
for 3 months  
 
Zhang,	2015  
(3) 
Double-
blind, 
RCT 
144 > 50 
years 
old  
Diagnosis of dementia of 
the Alzheimer’s type 
according to the diagnostic 
and statistical manual, 
diagnosis was confirmed by 
image test (CT/MRI), 
women/men aged 50-85, 
Hachinski ischemic score ≤ 
4, Hamilton depression 
rating ≤7, CDR=1 
Vascular dementia 
or any 
neurological 
disorder other 
than AD that 
contributed to 
dementia, severe 
heart, liverm or 
kidney disease, 
use of drugs that 
may affect 
cognitive function 
4 weeks prior to 
randomization, 
uncontrolled 
HTN, aphasia, 
hemiplegia 
31 Chinese herbal 
formular 
Yishen 
Huaxhuo 
decoction (100 
ml orally once 
a day, half an 
hour after 
breakfast) for 
12 months  
 
OUTCOMES MEASURED  
  
 All of the outcomes measured in this selective evidence medicine based review include 
patient oriented evidence. The outcomes measured include changes in Alzheimer’s symptoms 
based upon a neurologist, improvement of Alzheimer’s symptoms based on ADAS-cog and 
CDR-SOB clinical rating scale, and Alzheimer health related quality of life based on a 20-item 
questionnaire. The ADAS-cog is a 21-item scale used to assess the severity of cognitive 
impairments in patients with Alzheimer’s disease. It ranges from 0-70 (very severe) and 
evaluates selected aspects of attention, language, memory, orientation, praxis, and reasoning. 
The CDR-SOB sums up the ratings from six domains: memory, orientation, judgment, problem 
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solving, community affair, home and hobbies, and personal care. It ranges from 0-3 (3=severe 
dementia). The Akhondzadeh et al double-blind, randomized control trial measured improvement 
of cognitive function in patients with mild-to-moderate Alzheimer’s disease prior to and four 
months after the treatment of herbal medicine Salvia officinalis extract. The main efficacy 
measures were the ADAS-cog and CDR-SB and outcome measures were the change in ADAS-
cog and CDR-SB scores over the 4-month trial. Patients were evaluated by a neurologist at 
baseline and every 2 weeks after the Saliva officinalis extract was administered. The data was 
reported as a mean change in baseline with a standard deviation1.  
 The Tajadini et al double- blind, randomized control trial measured improvement of 
cognitive function in patients with mild-to-moderate Alzheimer’s disease prior to and three 
months after the treatment of herbal medicine Davaie Loban. This was assessed based on the 
ADAS-cog and CDR-SB clinical rating scale every 4 weeks during the study period of 12 weeks. 
This data was reported with statistical significant p values.  
 The Zhang et al double-blind, randomized control trial measured improvement of 
cognitive function in patient with mild Alzheimer’s disease prior to and 6 months after the 
treatment of herbal formula, Yishen Huazhuo decoction. This was measured using the ADAS-
cog and higher values indicating higher degree of deficit. The study also used a 20-item 
questionnaire designed to measure the patient’s ability to carry out daily activities such as 
medication management, food preparation, personal hygiene and transportation utilization. Each 
of these items rating between 0 and 10, where higher values denote higher severity of symptom. 
The data was reported as a mean change in baseline with standard deviation3.  
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RESULTS  
 This selective evidence based medicine review evaluates herbal medicine as a treatment 
for Alzheimer’s disease. The results of these studies were all presented in continuous data. All 
three studies were randomized with concealment to randomization. All of the patients, clinicians, 
and study workers were kept blind to which patients were in the treatment group for the duration 
of the study. 
 Akhondzadeh et al is a double-blind, randomized control trial that assesses the 
improvement in cognitive function of herbal medicine Salvia officinalis extract in patients with 
mild-to-moderate Alzheimer’s disease who are 50 years and older. The treatment group was 
compared to a visually matched placebo group. Thirty-nine participants were placed into one of 
the two groups: nineteen patients assigned to the herbal medicine group that received 60 
drop/day of S. officinalis extract and twenty patients assigned to the placebo group that received 
60 drops/day of placebo. The study measured improvement of cognitive function based on 
ADAS-cog and CDR-SOB scores over the trial at baseline and every 2 weeks after. Regarding 
both the ADAS-cog and CDR-SOB, there were no significant differences between the two 
groups in week 0 (baseline). The difference between the two protocols was significant at the end 
point (week 16). The changes at the endpoint compared with baseline for ADAS-cog were: -6.60 
+/- 1.63 (mean +/- SD) and 5.53 +/- 1.12 for Salvia extract and placebo, respectively. The 
changes at the endpoint compared with baseline for CDR-SOB were: -1.60 +/- 1.35 (mean +/- 
SD) and 0.73 +/- 0.41 for Salvia extract and placebo, respectively. At the conclusion of the 
study, it was determined there was a significant increase in cognitive function in Alzheimer’s 
patients with a statistically significant p-value of  <0.00011. 
Figure 2: Mean +/- SEM scores of the two protocols on the ADAS-cog score. ns, non-significant  
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Figure 3: Mean +/- SEM scores of the two protocols on the CDR-SB score. ns, non significant  
 
 
 
 
 
 
 
 
 
 
 
 
Tajadini et al is a double-blind, randomized control trial that assesses the improvement in 
cognitive function of herbal medicine Davaie Loban in patients with mild-to-moderate 
Alzheimer’s disease who are 50 years and older. The treatment group was compared to a visually 
matched placebo group. Fifty participants were placed into one of the two groups: twenty-five 
patients assigned to the herbal medicine Davaie Loban received (500 mg three times daily) and 
twenty-five patients assigned to placebo group. The study measured improvement of cognitive 
function based on ADAS-cog and CDR-SOB scores over intervention that lasted for 12 weeks. 
Regarding the ADAS-cog, there were no significant difference between the two groups in week 
0 (baseline) (p=0.751). However, after 4 and 12 weeks there was a significant difference in mean 
(SE) ADAS-cog scores between DL and placebo groups and it was lower in DL group 
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(p<0.001). Regarding the CDR-SOB, there was no significant decreases between the two groups 
in week 0 (baseline) (p=0.096). However, after 4 and 12 weeks there was a significant difference 
in mean (SE) CDR-SOB scores between DL and placebo groups and it was lower in DL group 
(p<0.001). At the conclusion of the study, it was determined there was a significant increase in 
cognitive function in Alzheimer’s patients with a statistically significant p-value of  <0.0012. 
Fig 2. Mean (SE) scores of ADAS-cog in DL and placebo group throughout study  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. Mean (SE) scores of CDR-SOB in DL and placebo group throughout study  
 
 
 
 
 
 
 
 
 
 
Zhang et al is a double-blind, randomized control trial that assesses the improvement in 
cognitive function of herbal formula Yishen Huazbuo decoction (YHD) in patients with mild 
Alzheimer’s disease who are 50 years and older. The treatment group was compared to donepezil 
hydrochloride (DH). 144 participants were place into one of the two groups: seventy-two patients 
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were assigned to the herbal formula YHD and seventy-two patients were assigned to the DH 
group. The study measured improvement of cognitive function based on ADAS-cog and ADL 
scores over the intervention that lasted for 24 weeks. The scores in YHD group significantly 
reduced in week 12 and 24, while the scores of DH group declined in week 24. The mean scores 
of ADAS-cog showed a decreased of 3.10 +/- 4.55 in YHD group and a decrease of 1.22 +/- 4.99 
in DH group during the 24 weeks treatment, with statistical significance of p-value <0.053. Both 
YHD and DH could improve scores of ADL, but without statistically significant difference 
between groups. At the conclusion of the study, it was determined there was a significant 
increase in cognitive function in Alzheimer’s patients with a statistically significant p-value of  
<0.053. 
Fig 2. Scores of ADAS-cog and ADL in YHD and DH group  
 
 
 
 
 
Table 2. Mean efficacy scores at all time points and change at week 24, 48 (Mean+/-SD) 
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DISCUSSION 
 
The three randomized controlled trials discussed in this review suggest that herbal 
medicine is an effective alternative treatment for Alzheimer’s disease. All three studies 
demonstrated a statistically significant improvement in the cognitive function measured with a 
statistical significance threshold set a p<0.05. This study showed that the herbal medicines was 
above all else in terms of word recall task, following commands, orientation, word recognition 
task, remembering test direction, spoken language, comprehension, and word-finding difficulty.  
All three studies in this selective evidence based medicine review demonstrated 
limitations. For two of the studies, sample size was the main limitation. Akhondzadeh et al had a 
sample size of thirty-nine and Tajadini et al had a sample size of fifty1,2. Another limitation was a 
moderate dropout rate. For instance, Akhondzadeh began their study with thirty-nine patients and 
ended with thirty1.  In the treatment group, 4 discontinued (2 consent withdraw and 2 lost to 
follow up) and in the control group, 5 discontinued (1 ineligible to continue, 2 consent withdraw, 
2 lost to follow up) thus the outcomes from these people that were not included in the analysis 
might have affected the significant of the results1. Tajadini began their study with fifty and ended 
with forty-four2. In the treatment group, 1 was lost due to follow up and in the control group, 5 
were lost due to follow up, thus the outcomes from these people that were not included in the 
analysis might have affected the significance of the results2. 
CONCLUSION 
  
 All three studies successfully demonstrated that there is a significant improvement in 
cognitive function of patients 50 years and older with mild-to-moderate Alzheimer’s disease 
following treatment with herbal medicine. Therefore, herbal medicine is an effective alternative 
Liebman│Herbal Medicine & Alzheimer’s Disease 11 
treatment for improving the cognitive function and reducing the symptoms of Alzheimer’s 
disease in patients 50 years and older.  
Despite this convincing evidence, further studies on human subjects with longer follow-
ups, larger sample sizes, and comparison to chemical drugs currently used for Alzheimer’s 
disease should be conducted. It would be important to create a study comparing herbal medicine 
to cholinesterase inhibitors or N-methyl-D-aspartate receptor blockers to see which method of 
treatment would be superior for treating symptoms of Alzheimer’s disease.  
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